结核分枝杆菌对吡嗪酰胺耐药的相关基因及耐药机制研究进展  

Research progress on genes and mechanism of Mycobacterium tuberculosis resistance to pyrazinamide

作　　者：周婷婷[1,2] 郑小曼 欧阳净 鲁雁秋 陈耀凯 ZHOU Ting-ting;ZHENG Xiao-man;OUYANG Jing;LU Yan-qiu;CHEN Yao-kai(Southwest University Medical Research Institute,Chongqing 400715,China;Science and Education Division,Chongqing Public Health Medical Center,Chongqing 400036,China;Infectious Disease Department,Chongqing Public Health Medical Center,Chongqing 400036,China)

机构地区：[1]西南大学医学研究院,重庆400715 [2]重庆市公共卫生医疗救治中心科教科,重庆400036 [3]重庆市公共卫生医疗救治中心感染科,重庆400036

出　　处：《中国防痨杂志》2022年第1期102-105,共4页Chinese Journal of Antituberculosis

基　　金：重庆市卫生计生委中医药科技项目(ZY201801003);重庆市科卫联合医学科研项目(2020GDRC004);重庆市科技局人才项目(cstc2021ycjh-bgzxm0275)。

摘　　要：吡嗪酰胺是结核病最重要的一线治疗药物之一,但结核分枝杆菌对其耐药性在逐年增长,目前对于结核分枝杆菌吡嗪酰胺的耐药基因的分子机制尚无定论。作者对结核分枝杆菌吡嗪酰胺的相关耐药基因pncA、rpsA、panD、fadD2及FAS-I的研究进展进行综述。Pyrazinamide is one of the most important first-line therapeutic drugs for tuberculosis,but the resistance of Mycobacterium tuberculosis to this drug is increasing year by year.At present,molecular mechanisms and drug resistance related genes of pyrazinamide is still inconclusive.The authors review research progress of pyrazinamide resistance related genes,including pncA,rpsA,panD,fadD2 and FAS-I.

关 键 词：分枝杆菌 结核 吡嗪酰胺 抗药性 基因 

分 类 号：R52[医药卫生—内科学] R446.5[医药卫生—临床医学]